An integrated overview of modern approaches to lead discovery Lead generation is increasingly seen as a distinct and success-determining phase of the drug discovery process. Over recent years, there have been major advances in the understanding of what constitutes a good lead compound and how to improve the chances of finding such a compound. Written by leading scientists and established opinion leaders from industry and academia, this book provides an authoritative overview of the field, as well as the theory, practice, and scope, of the principal Lead Generation Approaches in Drug Discovery, including:
-
The evolution of the lead discovery process, key concepts, current challenges, and future directions
-
Strategies and technologies driving the high-throughput screening (HTS) approach to lead discovery, including the shifting paradigms in the design of compound collections and best practice in the hit confirmation process
-
Knowledge-based in silico or "virtual" screening
-
Theory and practice of the fragment-based approach to lead discovery
-
The opportunities and challenges presented by multi-target drug discovery (MTDD)
-
De novo design of lead compounds and new approaches to estimating the synthetic accessibility of de novo–designed molecules
-
The impact of natural products on drug discovery, and potential of natural product–like compounds for exploring regions of biologically relevant chemical space
-
Using early screening of hits and leads for metabolic, pharmacokinetic, and toxicological liabilities to reduce attrition during the later phases of drug discovery
-
The utility of parallel synthesis and purification in lead discovery
With each topic supported by numerous case studies, this is indispensable reading for researchers in industry and academia who wish to keep up to date with the latest strategies and approaches in drug discovery.
ZORAN RANKOVIC is a Senior Research Fellow and Associate Director in Medicinal Chemistry at Schering-Plough Research Institute, UK. He received his PhD in organic chemistry from the University of Leeds (UK) before starting his medicinal chemistry career in 1995 at Organon, UK. Since then, working on projects over a range of therapeutic areas, including psychosis, analgesia, and cardiovascular and bone diseases, he gained extensive experience in all stages of the drug discovery process, including lead generation. From this work, Dr. Rankovic has authored or coauthored over fifty scientific publications, book chapters, and patents, and has given invited lectures at numerous international conferences.
RICHARD MORPHY is a medicinal chemistry section head at Schering-Plough Research Institute (SPRI) at Newhouse, Scotland. He has twenty years' experience in the pharmaceutical industry, previously working for Celltech and Organon on a wide range of oncology, inflammation, psychiatry, and analgesia projects. In addition to his extensive experience of the lead discovery process, he has a keen interest in the development of medicinal chemistry in emerging economies and is an opinion leader in the area of multi-target drug discovery.
